A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Patients must have a diagnosis of chronic migraine as defined by the IHS ICHD-3 guidelines (1.3 according to ICHD-3 [2018]), that is, a headache occurring on 15 or more days per month for at least the last 3 months, which has the features of migraine headache on at least 8 days per month
Participants Must Not:
Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches
Participants must not have a history of persistent headaches every day or cluster headaches
Participants must not have a history of head or neck injury that was associated with the start of migraine headaches or a change in the nature of their headaches
Participants must not have a history of brain tumors or birth defects of the brain
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo